Literature DB >> 27307251

The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome.

Mirjana Bećarević1.   

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disease that is characterized by the presence of thromboses and/or recurrent pregnancy losses (RPL). The persistent presence of antiphospholipid antibodies (aPL Abs): IgG and/or IgM isotypes of the anticardiolipin and/or anti-β2 glycoprotein I antibodies and lupus anticoagulant is mandatory for the laboratory diagnosis of APS. Due to the heating debate on the relevance of the IgM isotype of aPL Abs as a laboratory criterion defining APS, the focus of this article was to analyze whether both the IgG and IgM isotype of anti-annexin A5 Abs have equal relevance for clinical and serological features of patients with primary APS (PAPS). The IgG isotype of anti-annexin A5 Abs is associated with RPL in PAPS patients, although it is not elucidated whether these Abs are the cause or the consequence of RPL in PAPS. No data that could substantiate the association of the IgG and/or the IgM isotypes of anti-annexin A5 Abs with the presence of arterial and/or venous thromboses and/or their main complications in PAPS is available so far. However, the presence of clinical manifestations of the PAPS is increasing with the multiple positivity for aPL Abs and the IgM isotype of anti-annexin A5 Abs. The importance of the IgM isotype of anti-annexin A5 Abs in PAPS needs further elucidation due to the facts that majority of the available articles did not differentiate between both isotypes or only investigated the IgG isotype of anti-annexin A5 Abs.

Entities:  

Keywords:  Annexin A5; Anti-annexin A5 antibodies; IgG and IgM isotype; Primary antiphospholipid syndrome

Mesh:

Substances:

Year:  2016        PMID: 27307251     DOI: 10.1007/s11239-016-1389-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  39 in total

Review 1.  Annexins: from structure to function.

Authors:  Volker Gerke; Stephen E Moss
Journal:  Physiol Rev       Date:  2002-04       Impact factor: 37.312

2.  Antiphospholipid syndrome: interpretation of laboratory data.

Authors:  V Pengo
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

Review 3.  Anti-annexin V antibodies: are they prothrombotic?

Authors:  Gaëtan Esposito; Mathieu C Tamby; Youri Chanseaud; Amélie Servettaz; Loïc Guillevin; Luc Mouthon
Journal:  Autoimmun Rev       Date:  2005-01       Impact factor: 9.754

4.  Plasma annexin A5 level relates inversely to the severity of coronary stenosis.

Authors:  Lambertus J H van Tits; Waander L van Heerde; Gerly M van der Vleuten; Jacqueline de Graaf; Diederick E Grobbee; Lucy P L van de Vijver; Anton F Stalenhoef; Hans M Princen
Journal:  Biochem Biophys Res Commun       Date:  2007-03-12       Impact factor: 3.575

5.  Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications.

Authors:  J Nojima; H Kuratsune; E Suehisa; Y Futsukaichi; H Yamanishi; T Machii; Y Iwatani; Y Kanakura
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

6.  Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome.

Authors:  B de Laat; R H W M Derksen; I J Mackie; M Roest; S Schoormans; B J Woodhams; P G de Groot; W L van Heerde
Journal:  Ann Rheum Dis       Date:  2006-01-31       Impact factor: 19.103

7.  Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages.

Authors:  Nicola Bizzaro; Elio Tonutti; Danilo Villalta; Marilina Tampoia; Renato Tozzoli
Journal:  Arch Pathol Lab Med       Date:  2005-01       Impact factor: 5.534

Review 8.  Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases.

Authors:  L Iaccarino; A Ghirardello; M Canova; M Zen; S Bettio; L Nalotto; L Punzi; A Doria
Journal:  Autoimmun Rev       Date:  2011-04-17       Impact factor: 9.754

9.  The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Ljudmila Stojanović; Svetlana Ignjatović; Violeta Dopsaj
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

Review 10.  Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population.

Authors:  Anna Cederholm; Johan Frostegård
Journal:  Ann N Y Acad Sci       Date:  2007-06       Impact factor: 5.691

View more
  7 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

2.  Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Marija Sarić; Ljudmila Stojanovich; Duško Mirković; Violeta Dopsaj; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

Review 3.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

Review 4.  TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević
Journal:  Rheumatol Int       Date:  2016-10-04       Impact factor: 2.631

Review 5.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

Review 6.  The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome.

Authors:  Oscar Cabrera-Marante; Edgard Rodríguez de Frías; Manuel Serrano; Fernando Lozano Morillo; Laura Naranjo; Francisco J Gil-Etayo; Estela Paz-Artal; Daniel E Pleguezuelo; Antonio Serrano
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

7.  Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome.

Authors:  Ilan Volkov; Luciana Seguro; Elaine P Leon; László Kovács; Dirk Roggenbuck; Peter Schierack; Boris Gilburd; Andrea Doria; Maria G Tektonidou; Nancy Agmon-Levin
Journal:  Auto Immun Highlights       Date:  2020-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.